Royalty Pharma PE Ratio 2019-2021 | RPRX
Current and historical p/e ratio for Royalty Pharma (RPRX) from 2019 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Royalty Pharma PE ratio as of August 04, 2021 is 17.44.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
|Royalty Pharma PE Ratio Historical Data
||TTM Net EPS
||Finance - Miscellaneous Services
Royalty Pharma plc is a funder of biopharmaceutical industry. The compnay's portfolio includes royalties on commercial products, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta and Vertex's Kalydeco, Symdeko and Trikafta, and development-stage product candidates. Royalty Pharma plc is based in NEW YORK.